第二型轉麩胺酶（transglutaminase 2；TG2）為一多功能蛋白，具有轉麩胺酶活性、G蛋白活性、雙硫異構酶活性以及蛋白質激酶活性。在細胞中主要位於細胞質，但是亦分佈於細胞核、細胞膜、細胞表面，甚至可以分泌到細胞外。位於細胞表面的第二型轉麩胺酶可與integrin作用，進而促進細胞黏附。近來的文獻更進一步指出第二型轉麩胺酶與癌細胞的轉移有關。在此，我們使用高轉移性肺癌細胞株CL1-5及低轉移性細胞株CL1-0去探討第二型轉麩胺酶在肺癌細胞轉移中所扮演的角色以及控制其表現之機制。我們的結果顯示，降低第二型轉麩胺酶的表現量，或者在細胞培養時加入第二型轉麩胺酶抗體CUB7402會抑制CL1-5的移行和侵入。然而，加入第二型轉麩胺酶活性抑制劑對CL1-5的侵入和移行能力沒有影響。因此，第二型轉麩胺酶對肺癌細胞移行和侵入能力可能受其數量或分布所影響，而與活性無關。第二型轉麩胺酶在CL1-0的表現量可以由同時處理5-Aza-2’-deoxycystidine and trichostatin A或是分別刺激過氧化氫或腫瘤壞死因子而提高。但是，第二型轉麩胺酶在CL1-5的表現量僅能些微地被pyrrolidine dithiocarbamate或genistein降低。

Transglutaminase 2 (TG2) is a multifunctional protein, harboring transamidation, G protein, protein disulfide isomerase and protein kinase activities. It mainly localizes in the cytosol, but also distributes in the nucleus, cell membrane, cell surface, or even the exterior of the cell. Cell surface TG2 interacts with integrins, promoting cell adhesion. Recent findings further reveal the involvement of TG2 in tumor metastasis. Here, we further explore the role of TG2 in metastasis and the regulatory mechanism for TG2 expression using the highly metastatic lung cancer cell line CL1-5 and the low metastatic line CL1-0. Our results show that lowering TG2 expression or application of TG2 antibody (clone CUB7402) in cultures suppresses cell migration and invasion in CL1-5. However, inclusion of a TG2 inhibitor does not affect these events, suggesting that the amount or the distribution of TG2, but not the activity of TG2, play a role in tumor metastasis. Low expression levels of TG2 in CL1-0 are increased by the combined treatment of 5-Aza-2’-deoxycystidine and trichostatin A as well as either hydrogen peroxide or tumor necrosis factor-α, By contrast, expression of TG2 in CL1-5 is only slightly decreased by pyrrolidine dithiocarbamate and genistein.

中文摘要 1
英文摘要 2
縮寫檢所表 3
第壹章 緒論 5
第貳章 實驗材料方法 13
第叁章 實驗結果 19
第肆章 討論 23
第伍章 圖表 26
第陸章 參考文獻 38

1.Siegel, R., D. Naishadham, and A. Jemal, Cancer statistics, 2013. CA Cancer J Clin, 2013. 63(1): p. 11-30.
2.Wender, R., et al., American Cancer Society lung cancer screening guidelines. CA Cancer J Clin, 2013. 63(2): p. 107-17.
3.Witt, C., European respiratory society/american thoracic society/international association for the study of lung cancer international multidisciplinary classification of lung adenocarcinoma: state of the art. J Thorac Oncol, 2011. 6(8): p. 1451.
4.Hecht, S.S., Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act. Nicotine Tob Res, 2012. 14(1): p. 18-28.
5.Hecht, S.S., F. Kassie, and D.K. Hatsukami, Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. Nat Rev Cancer, 2009. 9(7): p. 476-88.
6.Humans, I.W.G.o.t.E.o.C.R.t., Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum, 2004. 83: p. 1-1438.
7.Vineis, P., et al., Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ, 2005. 330(7486): p. 277.
8.Johnson, K.C., et al., Lifetime residential and workplace exposure to environmental tobacco smoke and lung cancer in never-smoking women, Canada 1994-97. Int J Cancer, 2001. 93(6): p. 902-6.
9.Amabile, J.C., et al., Multifactorial study of the risk of lung cancer among French uranium miners: radon, smoking and silicosis. Health Phys, 2009. 97(6): p. 613-21.
10.Darby, S., et al., Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ, 2005. 330(7485): p. 223.
11.Krewski, D., et al., A combined analysis of North American case-control studies of residential radon and lung cancer. J Toxicol Environ Health A, 2006. 69(7): p. 533-97.
12.Chiang, T.A., et al., Mutagenicity and polycyclic aromatic hydrocarbon content of fumes from heated cooking oils produced in Taiwan. Mutat Res, 1997. 381(2): p. 157-61.
13.Yu, I.T., et al., Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women. Cancer Res, 2006. 66(9): p. 4961-7.
14.Mumford, J.L., et al., Mouse skin tumorigenicity studies of indoor coal and wood combustion emissions from homes of residents in Xuan Wei, China with high lung cancer mortality. Carcinogenesis, 1990. 11(3): p. 397-403.
15.Kauppinen, T., et al., Mortality and cancer incidence of workers in Finnish road paving companies. Am J Ind Med, 2003. 43(1): p. 49-57.
16.Olsson, A., et al., A case-control study of lung cancer nested in a cohort of European asphalt workers. Environ Health Perspect, 2010. 118(10): p. 1418-24.
17.Couraud, S., et al., Lung cancer in never smokers--a review. Eur J Cancer, 2012. 48(9): p. 1299-311.
18.Stabile, L.P., et al., Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res, 2002. 62(7): p. 2141-50.
19.Siegfried, J.M., Women and lung cancer: does oestrogen play a role? Lancet Oncol, 2001. 2(8): p. 506-13.
20.Siegfried, J.M., Hormone replacement therapy and decreased lung cancer survival. J Clin Oncol, 2006. 24(1): p. 9-10.
21.Cheng, Y.W., et al., Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus-16/18-infected lung tumorigenesis. Clin Cancer Res, 2008. 14(22): p. 7173-9.
22.Chiou, H.L., et al., The presence of human papillomavirus type 16/18 DNA in blood circulation may act as a risk marker of lung cancer in Taiwan. Cancer, 2003. 97(6): p. 1558-63.
23.Cheng, Y.W., et al., The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res, 2001. 61(7): p. 2799-803.
24.Begg, G.E., et al., Mechanism of allosteric regulation of transglutaminase 2 by GTP. Proc Natl Acad Sci U S A, 2006. 103(52): p. 19683-8.
25.Lorand, L. and R.M. Graham, Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol, 2003. 4(2): p. 140-56.
26.Nakaoka, H., et al., Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science, 1994. 264(5165): p. 1593-6.
27.Kiraly, R., M. Demeny, and L. Fesus, Protein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional protein. FEBS J, 2011. 278(24): p. 4717-39.
28.Bruce, S.E. and T.J. Peters, The subcellular localization of transglutaminase in normal liver and in glucagon-treated and partial hepatectomized rats. Biosci Rep, 1983. 3(12): p. 1085-90.
29.Zemskov, E.A., et al., The role of tissue transglutaminase in cell-matrix interactions. Front Biosci, 2006. 11: p. 1057-76.
30.Mishra, S. and L.J. Murphy, Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem, 2004. 279(23): p. 23863-8.
31.Scarpellini, A., et al., Heparan sulfate proteoglycans are receptors for the cell-surface trafficking and biological activity of transglutaminase-2. J Biol Chem, 2009. 284(27): p. 18411-23.
32.Balklava, Z., et al., Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts: the active-state conformation of the enzyme does not affect cell motility but is important for its secretion. J Biol Chem, 2002. 277(19): p. 16567-75.
33.Zemskov, E.A., et al., Unconventional secretion of tissue transglutaminase involves phospholipid-dependent delivery into recycling endosomes. PLoS One, 2011. 6(4): p. e19414.
34.Telci, D., et al., Increased TG2 expression can result in induction of transforming growth factor beta1, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide. J Biol Chem, 2009. 284(43): p. 29547-58.
35.Park, K.S., et al., Depletion of nucleophosmin via transglutaminase 2 cross-linking increases drug resistance in cancer cells. Cancer Lett, 2009. 274(2): p. 201-7.
36.Robitaille, K., et al., Calphostin C-induced apoptosis is mediated by a tissue transglutaminase-dependent mechanism involving the DLK/JNK signaling pathway. Cell Death Differ, 2008. 15(9): p. 1522-31.
37.Szondy, Z., et al., Transglutaminase 2-/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. Proc Natl Acad Sci U S A, 2003. 100(13): p. 7812-7.
38.Haroon, Z.A., et al., Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J, 1999. 13(13): p. 1787-95.
39.Fisher, M., et al., Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring. Matrix Biol, 2009. 28(1): p. 20-31.
40.Iismaa, S.E., et al., Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev, 2009. 89(3): p. 991-1023.
41.Mantovani, A., et al., Cancer-related inflammation. Nature, 2008. 454(7203): p. 436-44.
42.Grivennikov, S.I., F.R. Greten, and M. Karin, Immunity, inflammation, and cancer. Cell, 2010. 140(6): p. 883-99.
43.Quan, G., et al., TGF-beta1 up-regulates transglutaminase two and fibronectin in dermal fibroblasts: a possible mechanism for the stabilization of tissue inflammation. Arch Dermatol Res, 2005. 297(2): p. 84-90.
44.Kuncio, G.S., et al., TNF-alpha modulates expression of the tissue transglutaminase gene in liver cells. Am J Physiol, 1998. 274(2 Pt 1): p. G240-5.
45.Johnson, K., et al., Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. Am J Pathol, 2001. 159(1): p. 149-63.
46.Suto, N., K. Ikura, and R. Sasaki, Expression induced by interleukin-6 of tissue-type transglutaminase in human hepatoblastoma HepG2 cells. J Biol Chem, 1993. 268(10): p. 7469-73.
47.Verma, A. and K. Mehta, Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat, 2007. 10(4-5): p. 144-51.
48.Mangala, L.S., et al., Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene, 2007. 26(17): p. 2459-70.
49.Ai, L., et al., The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis, 2008. 29(3): p. 510-8.
50.Chen, G., et al., Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res, 2002. 8(7): p. 2298-305.
51.Park, M.K., et al., Transglutaminase-2 induces N-cadherin expression in TGF-beta1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation. Eur J Cancer, 2013. 49(7): p. 1692-705.
52.Park, K.S., et al., Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol, 2010. 136(4): p. 493-502.
53.Kong, L. and R.J. Korthuis, Melanoma cell adhesion to injured arterioles: mechanisms of stabilized tethering. Clin Exp Metastasis, 1997. 15(4): p. 426-31.
54.Lentini, A., et al., Transglutaminases: key regulators of cancer metastasis. Amino Acids, 2013. 44(1): p. 25-32.
55.Di Giacomo, G., et al., In vivo evaluation of type 2 transglutaminase contribution to the metastasis formation in melanoma. Amino Acids, 2009. 36(4): p. 717-24.
56.Sanz-Moreno, V., Tumour invasion: a new twist on Rac-driven mesenchymal migration. Curr Biol, 2012. 22(11): p. R449-51.
57.Keshamouni, V.G., et al., Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res, 2006. 5(5): p. 1143-54.
58.Olsen, K.C., et al., Transglutaminase 2 and its role in pulmonary fibrosis. Am J Respir Crit Care Med, 2011. 184(6): p. 699-707.
59.Mangala, L.S., et al., Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer, 2005. 4: p. 33.